Elevations in Alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse

Hepatology

Volumn 49, Issue 5, 2009, Pages 1442-1448

  Basso, Monica ^a   Giannini, Edoardo G ^a   Torre, Francesco ^a   Blanchi, Sabrina ^a   Savarino, Vincenzo ^a   Picciotto, Antonio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA2A INTERFERON; ALPHA2B INTERFERON; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; BLOOD; ENZYMOLOGY; GENETICS; MIDDLE AGED; RECURRENT DISEASE;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECURRENCE; RIBAVIRIN; RNA, VIRAL;

EID: 66149099243     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22810     Document Type: Article

References (24)

1. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 202;123:2082-2099.
2. Davis GL. Monitoring of viral levels during therapy of hepatitis C. HEPATOLOGY 2002;36(Suppl. 1):S145-S151.
3. Lee SS. Review article: Indicators and predictors of response to anti-viral therapy in chronic hepatitis C. Aliment Pharmacol Ther 2003;17:611-621.
4. Civeira MP, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol 1999;31(Suppl. 1):S237-S243.
5. Hung CH, Lee CM, Lu SN, Wang JH, Tung HD, Chen TM, et al. Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy? J Gastroenterol Hepatol 2002;17:1307-1311.
6. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alpha-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
7. Lindsay KL. Introduction to therapy of hepatitis C. HEPATOLOGY 2002; 36(Suppl. 1):S114-S120.
8. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22: 696-699.
9. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: A guide for clinicians. CMAJ 2005;172:367-379.
10. Thurairajah PH, Thorburn D, Hubscher S, White A, Lai WK, O'Donnell K, et al. Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C. Aliment Pharmacol Ther 2007;25:1293-1300.
11. Nagashima M, Kudo M, Chung H, Ishikawa E, Inoue T, Nakatani T, et al. Elevated serum ALT levels during pegylated interferon monotherapy may be caused by iron overload. Intervirology 2008;51(Suppl. 1):S76-S85.
12. Koskinas J, Tibbs C, Saleh MG, Pereira LM, McFarlane IG, Williams R. Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients. J Med Virol 1995;45:29-34.
13. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
14. Kaplan MM. Alanine aminotransferase levels: What's normal? Ann Intern Med 2002;137:49-51.
15. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
16. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-965.
17. Marcellin P, Heathcote JA, Craxì A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen? J Hepatol 2007;47:580-587; erratum: J Hepatol 2008;48: 526.
18. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000;118:346-355.
19. Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky JM, et al. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 2007;133:1132-1143.
20. Abe S, Narita R, Matsuhashi T, Oto T, Tabaru A, Otsuki M. Increased soluble IL-2 receptor levels during interferon and ribavirin treatment are associated with a good response in genotype 2a/2b patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2008;20:373-378.
21. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. HEPATOLOGY 2000;32:818-823.
22. Gerotto M, Dal Pero F, Bortoletto G, Ferrari A, Pistis R, Sebastiani G, et al. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol 2006;44:83-87.
23. Kadam JS, Gonzalez SA, Ahmed F, Menezes A, Jacobson IM. Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin. Dig Dis Sci 2007;52: 2525-2530.
24. Ferraro D, Giglio M, Bonura C, Di Marco V, Mondelli MU, Craxì A, et al. Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: Performance of the transcription-mediated amplification assay. J Viral Hep 2008;15:66-70.